Cost-effectiveness assessment of orphan drugs: A scientific and political conundrum

Applied Health Economics and Health Policy

Volumn 11, Issue 1, 2013, Pages 1-3

  Simoens, Steven ^a   Picavet, Eline ^a   Dooms, Marc ^b   Cassiman, David ^b   Morel, Thomas ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

COST EFFECTIVENESS ANALYSIS; HUMAN; REVIEW;

COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; NETHERLANDS; ORPHAN DRUG PRODUCTION; POLITICS; RARE DISEASES; REIMBURSEMENT MECHANISMS;

EID: 84873476022     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-012-0004-y     Document Type: Review

References (12)

1. Advice on agalsidase alfa (Replagal®) and agalsidase beta (Fabrazyme®) for the indication 'Fabry disease'. Diemen: CVZ, 2012. http://www.cvz.nl/binaries/content/documents/cvzinternet/nl/documenten/ rubriek+zorgpakket/acp/1209/acp1209-7a-agalsidase.pdf. Accessed 17 Oct 2012.
2. Advice on alglucosidase alfa (Myozyme®) for the indication 'Pompe disease'. Diemen: CVZ, 2012. http://www.cvz.nl/binaries/content/documents/ cvzinternet/nl/documenten/rubriek+zorgpakket/acp/1209/acp1209-08a-alglucosidase. pdf. Accessed 17 Oct 2012.
3. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
4. NICE to assess high cost low volume drugs. London: Department of Health, 2012. http://www.dh.gov.uk/health/2012/07/very-high-cost-drugs/. Accessed 17 Oct 2012.
5. Sheldon T. Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs. BMJ. 2012;345:e5461.
6. Argument of the Academic Medical Center in response to the preliminary advice from the Dutch Healthcare Insurance Board (CVZ) to stop reimbursement of Fabrazyme and Replagal. 2012. http://www.rarediseaseblogs.net/2012/09/24/ argument-of-the-academic-medical-center-in-response-to-the-preliminary-advice- from-the-dutch-healthcare-insurance-board-cvz-to-stop-reimbursement-of- fabrazyme-and-replagal/. Accessed 25 Oct 2012.
7. Simoens S, Cassiman D, Dooms M, et al. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs. 2012;72(11):1437-43.
8. Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics. 2005;31(3):164-8.
9. European Commission. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Off J Eur Commun. 2000; L18(1): 1-5.
10. Simoens S, Dooms M. Market access of orphan drugs: one size fits all? Hosp Pharm Eur. 2012;62:59-63.
11. Hughes-Wilson W, Palma A, Schuurman A, et al. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7(1):74.
12. ZonMw. The risks of conditional reimbursement: stopping can be more difficult than not starting! 2012. http://www.zonmw.nl/nl/projecten/project- detail/the-risks-of-conditional-reimbursement-stopping-can-be-more-difficult- than-not-starting/samenvatting/. Accessed 17 Oct 2012.